IL1B and cancer: As our present data suggests that the novel pain cascade may be important for the development of cancer-induced pain, we propose that the components of this novel pain cascade, IL-1β (cancer-inoculated region) → ephrin B1 (DRGs) → NR2B (spinal cord), represent potential drug targets for the treatment of cancer-induced pain.